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to non-breakthrough drugs, trials supporting breakthrough drugs had a smaller sample
size (median 401 vs 604, P¼.047), were less likely to evaluate experimental cytotoxic
chemotherapy or endocrine therapy than targeted therapy (0% vs 10%, P¼.004), and
were less often randomized (60% vs 84%; P¼.009) or double-blind (15% vs 46%,
P¼.001). A similar proportion of trials supporting breakthrough and non-break-
through drugs approved for palliative intent showed substantial clinical benefit using
ESMO-MCBS v1.1 (36% vs 29%; P¼.45). There were too few trials performed with
curative intent (n¼ 10) to perform statistical testing.
Conclusions: Compared to non-breakthrough drugs, trials of breakthrough drugs are
smaller and more likely to be single-arm and not double-blinded. A similarly low pro-
portion of breakthrough and non-breakthrough cancer drugs met the standard of sub-
stantial clinical benefit as applied in ESMO-MCBS v1.1.
Legal entity responsible for the study:Hospital de la Santa Creu i Sant Pau.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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1Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia,
2Pharmacy, University Clinic Golnik, Golnik, Slovenia, 3University of Ljubljana, Faculty of
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Background: In EU, novel anticancer drugs must obtain an EMAmarketing authoriza-
tion (EMAMA) through a centralized procedure, while their reimbursement is not
centralized, thus leading to different lag times in drug access for EU citizens. In
Slovenia, the reimbursement procedure is within the jurisdiction of the National
Health Insurance Institute. ESMOMagnitude of Clinical Benefit Scale (ESMO-MCBS)
was developed to aid oncologists and patients in informed treatment decisions, but
may also assist health care authorities in decision-making. Therefore, time to EMAMA
and reimbursement in Slovenia were assessed in relation to ESMO-MCBS.
Methods: Anticancer therapies for solid tumors with ESMO-MCBS scores determined
by the ESMO expert panels and published until Dec 31st 2017 were reviewed. Drugs
reimbursed before Jan 1st 2008 and before Jan 1st 2012 for oral and parenteral drugs,
data on reimbursement in
from www.ema.europa.
EMA: 39 targeted, 9
separately. Until data
lock, 46/51 therapies passed national reimbursement, 1 was rejected at reimbursement
and 4 were pending reimbursement decision. Of the 46 reimbursed drugs, 24 had a
high ESMO-MCBS score (A-B, 4-5), indicating a substantial clinical benefit, and 22
had a low ESMO-MCBS score (C, 1-3). Their median time to EMAMAwas 398 d (98 -
615 d) with no difference between high vs low ESMO-MCBS (377 vs 398 d). Median
time to national reimbursement was 429 d (154 - 892 d) again with no difference
between high vs low ESMO-MCBS (451 vs 416 d). This resulted in a total median time
to drug access of 762 d (373 – 1426 d).
Conclusions: Althoughmost novel anticancer therapies are available in Slovenia, the
median times to EMAMA and to reimbursement decision are above one year each.
This is well overdue for cancer patients. Neither time seem to differ by ESMO-MCBS,
possibly because the majority of drugs was not assigned a score at the time of decision-
making. Hopefully, a better integration of ESMO-MCBS is forthcoming.
Legal entity responsible for the study:All authors are responsible for the conduction
of the study and its results.
Funding:Has not received any funding.
Disclosure: T. Cufer: Advisory boards and/or provided lectures: AstraZeneca,
Boehringer-Ingelheim, BMS, Roche, MSD, Pfizer. All other authors have declared no
conflicts of interest.
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Background: Targeted prevention by RRS inmutation carriers ( first test the index case
with BC or EOC and , if positive, their family ) saves lives. BGMs rates: EOC (12 - 18%),
BC ( 1- 5%). BRCA1 carriers have a 35 - 60% EOC risk and 65% for BC; BRCA2 12-
25% and 45% respectively. RRS prevents 80-90%. Does this also represent value for
money compared to no prevention with treatment upon occurrence?
Methods: A patient level simulation was used: 50 yr time frame and all cause mortality
endpoint. Assumptions: 1) all index cases and female family had BGM 2) all unaffected
carriers had RRS – bilateral salpingo-oopherectomy (RRBSO) and bilateral mastec-
tomy (RRM) 3) 26,316 and 2786 BC and EOC per year in Canada 4) BGM rate in EOC
12.6% ( 61.6% BRCA1; 38.4% BRCA 2) ; 4.7% in BC ( 51% BRCA1, 49% BRCA2) 5)
test 10 relatives if index case positive ( 50% risk) and test 20 if 10 positive (25% risk) 6)
prevention by RRS for EOC is 84% and 90% for BC 7) Standard therapy cures 50%
EOC and 90% of BC. Costs: BRCA testing/counselling $1000; RRBSO $9080; RRM
$5833; EOC chemotherapy $34,412 / year and BC one time cost $23,796; palliative care
costs EOC $14,687, BC $29,993. Cancer -related utilities 0.5 to 0.72 for EOC and BC
0.71 to 0.77 .
Results: 29,102 index cases (1yr). 1668 had BRCAmutation as did 1593 10 and 275 200
relatives. Cases prevented: EOC 270 and BC 426. Total 50 year cost for testing/RRS
cohort was $255 million and $285 million in the control cohort. ICER ( incremental
cost effectiveness ratio) was - $7901 per quality adjusted life year ( dominant).
Sensitivity analyses showed less cost effective ICER as testing /RRS rates fell. At real
world rates e.g. 44% RRBSO and 21%RRM, ICER was $20,176. All probabilistic sensi-
tivity analyses remained in the cost-effective quadrant (North American ICER<
$100,000).
Conclusions: Targeting the high risk for RRS saves lives and is cost-effective under a
wide range of inputs. These data are conservative as excluded are the indirect costs of
treatment i.e. family/societal costs and increasing drug costs. Healthcare systems must
ensure as close to 100% BGM / RRS rates as this saves the most lives,is cost efficacious
and also saves money.
Legal entity responsible for the study: Paul Hoskins.
Funding: AstraZeneca.
Disclosure: P. Hoskins: Advisory boards: AstraZeneca, Roche, Pfizer, Purdue. A.
Ecclestone: Funding to do analysis for this paper: AstraZeneca. M. Hurry, M. Dyer:
Employee: AstraZeneca.
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Background:Mutations in BRCA1 and BRCA2 are linked to 5–10% of breast cancer
cases, often resulting in worse outcomes than non-hereditary cases. Across Europe,
genetic testing and optimal management of BRCAmutation carriers face a number of
barriers.
Methods:We developed seven country profiles: France, Germany, Ireland, Israel, Italy,
Sweden and UK.We examined barriers and opportunities in the policy landscape;
guideline and testing criteria; advocacy efforts; access to genetic testing and counselling
and ongoing support and protection. The profiles were based on pragmatic literature
review and qualitative interviews with national level experts including health professio-
nals, researchers and patient representatives.
Results: Preliminary findings currently being verified by the experts include:
Oncogenetic testing is integrated in few national (breast) cancer policies, but all selected
countries have criteria for BRCA genetic testing. Some countries, e.g. Ireland and
Sweden, have stricter eligibility criteria, limiting access. BRCA-related advocacy activ-
ities seem sparse. However, demand for genetic testing has soared. In France for exam-
ple, the number of women tested increased fivefold between 2003 and 2016. Genetic
BRCA testing is free of charge in all selected countries except Italy, where it is only free
in certain regions. However, women still may face long wait times and geographical
inequalities in service provision due to a lack of appropriately trained healthcare profes-
sionals. In three of the selected countries, genetic counselling is not mandatory and in
many countries availability of genetic counsellors is low, creating a bottleneck to service
provision.
Conclusions: This research identified opportunities and recommendations for patients
and policymakers to understand what is needed to ensure European women whomay
be at risk of carrying BRCAmutations can access and utilise high quality services along
the whole patient journey.
Legal entity responsible for the study: The Health Policy Partnership.
Funding: Pfizer Inc.
Disclosure:M. Thrift-Perry: Employee: Pfizer Inc.; Supported the Health Policy
Partnership research: Pfizer Inc. All other authors have declared no conflicts of interest.
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Background: Cancer is one of the leading causes of death worldwide. Most deaths from
cancer occurs in low- andmiddle- income countries, which might be explained by the
delayed presentation of the cancer patient. Inadequate public awareness of signs and
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symptoms of cancer and its risk factors is one of the factors related to this. Our study
aimed to assess the level of public awareness of cancer prevalence, symptoms and signs
as well as risk factors in Gaza.
Methods: This is a cross-sectional study conducted from September to October 2017 in
the Gaza-Strip, Palestine. Stratified sampling was used to recruit three major hospitals
and ten high schools. A previously pilot-tested, Arabic version of the Cancer Awareness
Measure (CAM) questionnaire, which is a validated standardized questionnaire to
measure public cancer awareness, was used. It involves four sections: sociodemo-
graphics, awareness of cancer prevalence, cancer symptoms and alarming signs, and
cancer risk factors. Adults (aged18 years) visiting or admitted to any of the three hos-
pitals, and adolescents (aged 15-17 years) in any of the ten schools were recruited for
face-to-face interviews. Patients and visitors to oncology departments were ineligible.
Informed consent and ethical approval were obtained. Data were analyzed with SPSS
(version 23).
Results:A total of 2886 participants completed the CAM questionnaire (of 3033
approached; response rate was 95.2%). 1483 (51.4%) were women, and 1457 (50.5%)
were adolescents. Overall, 2220 (76.9%) identified breast cancer as the most common
cancer among women in the Gaza-Strip but only 196 (6.7%) identified colorectal can-
cer as the most common cancer amongmales. 1885 (65.2%) thought that the chance of
getting cancer is not related to age. A lumpwas the most commonly recognized cancer
symptom (n¼ 2227, 77.1%) while change of bowel habit was the least (n¼ 670,
23.2%). Smoking was the most frequently recognized cancer risk factor (n¼ 2215,
76.7%) and eating less than 5 portions of fruit and vegetables a day was the least
(n¼ 514, 17.8%). The overall mean score for awareness of cancer symptoms is 3.56
1.7 out of 8 and that of risk factors is 7.96 3.1 out of 16.
Conclusions: Level of cancer awareness in Gaza is low. Educational interventions to
raise public awareness of cancer are urgently required.
Legal entity responsible for the study: PalestinianMinistry of Health.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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patients from Bronx, New York
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Background: Racial and ethnic disparities in cancer care are well described. Lack of
access to primary care physicians (PCPs) may be an important contributor to dispar-
ities attributed to race and ethnicity. This study examined the effects of primary care
access onmortality in lung cancer (LC) patients (pts) in an underserved community.
Methods:Medical records of all pts newly-diagnosed with primary lung cancer between
2012-2016 at a NCI-designated cancer center in the Bronx were reviewed.
Demographic data and PCP status were collected. Addresses were correlated with the
Health Resources and Services Administration (HRSA) database to identify residences
located in primary care shortage areas (PCSAs). Survival data from time of first imaging
to death or the end of follow-up on January 1, 2018 were recorded. Data analysis was
performed via univariate methods. Survival analysis was performed using Kaplan-
Meier and Cox hazards modeling.
Results:Among 1062 pts, 874 (82%) resided in a PCSA, 314 (30%) were Hispanic (H),
and 445 (42%) were African-American (AA). Hs and AAs were more likely to reside in
PCSAs (p¼ 0.0002 and p¼ 0.0008) and in ZIP codes with lower income (both
p< 0.0001). Hs and AAs were more likely to depend on public insurance (p¼ 0.01 and
p¼ 0.02). Pts who live in PCSAs presented at higher stages at the time of diagnosis
(p¼ 0.03) and were diagnosed predominantly in inpatient settings with acute symp-
toms (p< 0.0001) rather than outpatient clinics (p¼ 0.0002). In the overall popula-
tion, PCSA residence (mean: 24 vs. 30 months, p¼ 0.03, HR¼ 1.27) and no established
PCP (mean: 22 vs. 28 months, p< 0.0001, HR¼ 1.50) were associated with increased
all-cause mortality. In Coxmodeling adjusting for stage at diagnosis and PCSA resi-
dence, lack of established PCP still predicts increased mortality (p¼ 0.03, HR¼ 1.20).
Conclusions: Among new pts with LC, lack of established PCP is associated with
increased mortality. Hs and AAs are more likely to reside in PCSAs, suggesting the link
between increasedmortality and race/ethnicity may bemediated by lack of access to
primary care. Our results demonstrate that effective health policy efforts to reduce lung
cancer mortality must include approaches to improve access to primary care.
Legal entity responsible for the study: Albert Einstein School of Medicine, Montefiore
Medical Center.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Sorensen1, U.N. Lassen1
1Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen,
Denmark, 2Unit of Survivorship, Danish Cancer Society Research Center, Copenhagen,
Denmark
Background: Referral pattern to phase 1 oncology trials is a highly relevant topic as the
rapid development of new anticancer agents requires increased recruitment to early
clinical trials. In this study, we investigated possible recruitment bias. The objective was
to compare the socioeconomic position (SEP) and region of residence of patients
referred to the Phase 1 Unit at Copenhagen University Hospital to a matched control
group. Moreover, we investigated the influence of SEP on the inclusion in trials.
Methods:Data from the Danish registries were compiled based on the civil registration
number of patients referred to the Phase I Unit from 2005 to 2016. The association
between SEP and referral was examined in a conditional logistic regression analysis
based on referred patients and a matched control group.We adjusted for number of
cancers, M-stage, comorbidity and psychological disturbances. The association
between SEP and enrolment once referred was examined in a Cox regression analysis.
Results: 1255 patients were referred. 1143 of these patients were eligible for this study.
Complete data for analyses were available for 1026 patients and 229,788 controls
matched on age, gender, type of cancer, year of diagnosis and time from diagnosis to
referral. As barriers for referral, we identified short education as compared to long (OR
0.57, 95% CI 0.47-0.69), being outside workforce as compared to being within (OR
0.67, 95% CI 0.56-0.80), living alone as compared to living with a partner (OR 0.85,
95%CI 0.74-0.99) and living far from the Phase 1 Unit 0.34 as compared to living close
to (95% CI 0.29-0.40). 252 patients enrolled in trials. Once referred, the socioeconomic
parameters did not affect enrolment.
Conclusions: In this single-center study, patients’ SEP and region of residence affected
referral pattern to phase 1 trials. This suggests inequality in the access to phase 1 trials.
Legal entity responsible for the study:Danish Cancer Society Research Center,
Copenhagen, Denmark.
Funding: A.P. Møller Foundation, Knæk Cancer funds, The Health Foundation.
Disclosure: All authors have declared no conflicts of interest.
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Background: Breast cancer is the most common type of female cancer in Egypt and
world wide. Most of the cases present as locally advanced or metastatic rather than early
stages in Egypt. There is no data to assess waiting times in the Egyptian breast cancer
patient journey from developing first symptom until initiating treatment.
Methods: This is a descriptive study in which the electronic records and paper notes of
200 patients presenting from April until September 2016 to a public non governmental
breast cancer centre in Cairo were reviewed for different waiting times. The wait time
from developing the first symptom until commencing treatment was divided into
stages; Symptom to call (booking an appointment), call to review , review to diagnosis,
diagnosis to multidisciplinary teammeeting (MDT) andMDT to first therapy.
Results: The average time from developing symptom to booking an appointment
(patient factor) was 131 days /4.4 months. The time lag from booking until medical
review was 47 days /1.5 months. This is because of the booking systemwaiting list. The
mean time taken from review until getting a final diagnosis was 11 days. All cases were
discussed in theMDT and therapy ensued theMDT by 17 days in average. Themean in
hospital waiting time (time from review until commencing treatment whether surgery,
systemic therapy or radiotherapy) was 37 days while the mean time for the whole jour-
ney (symptom to treatment) was 214 days /7.1 months. Patients contributed to 61% of
the wait time (131 days / 4.4 months) whereas the provider contributed by 39%with
average of less than 3months.
Conclusions: Patients contributed to the biggest part of the delay. The second factor
was the booking systemwaiting list. Once reviewed by the medical team the process
was accelerated. This indicates a need to improve public awareness of breast cancer
symptoms and facilitate patient access to services.
Legal entity responsible for the study: Baheya Research Centre (BRC).
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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